Diagnosing Diabetes Mellitus With Glycated Haemoglobin in Newly Diagnosed HIV-positive Patients in Buffalo City Municipality, South Africa: A Cross-sectional Study

Olufunso O. Sogbanmu1, 2, *, Larry O. Obi2, Daniel T. Goon3, Anthony Okoh1, 2, Benson Iweriebor1, 2, Uchechukwu. U. Nwodo1, 2, Anthony I. Ajayi4, Tennison O. Digban1, 2
1 SAMRC Microbial Water Quality Monitoring Centre, University of Fort Hare, Alice, South Africa
2 Applied and Environmental Microbiology Research Group (AEMREG), Department of Biochemistry and Microbiology, University of Fort Hare, Alice, South Africa
3 Faculty of Health Sciences, University of Fort Hare, Alice, South Africa
4 Department of Social Sciences, University of Fort Hare, Alice, South Africa

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 3011
Abstract HTML Views: 2401
PDF Downloads: 591
ePub Downloads: 470
Total Views/Downloads: 6473
Unique Statistics:

Full-Text HTML Views: 1600
Abstract HTML Views: 1148
PDF Downloads: 389
ePub Downloads: 297
Total Views/Downloads: 3434

Creative Commons License
© 2019 Sogbanmu et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the University of Fort Hare, Alice, South Africa; Tel: +27730376528; E-mail:



The HbA1c estimates long-term glycaemic control in individuals. However, scanty data exist on the determination of Diabetes Mellitus (DM) in newly diagnosed HIV patients using the HbA1c screening tool in the South African context. Thus, this study examines the prevalence of diabetes mellitus in newly diagnosed HIV-positive patients in Buffalo City Municipality, East London, South Africa.


This was a cross-sectional study of 335 newly HIV-diagnosed patients between August 2016 and July 2017. Demographic (age, gender, residence, employment status and level of education) and behavioural variables (smoking and alcohol use (past 30 days)) were by self-reporting. Information on HbA1c and other clinical variables were obtained from the medical records of the patients. Diabetes mellitus was defined based on the Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) 2017 guideline of HbA1c of above 6.5%. Weight and height were measured using standard protocols. Logistic regression analyses were applied to determine the predictors of abnormal glycated haemoglobin.


Majority of the participants were female (72%). The prevalence of patients with HbA1c greater than 6.5% was 6%. The multivariate analysis indicates only age (p=0.031) and race (0.019) significantly shows a correlation to increase the risk of development of DM in newly diagnosed HIV positive patients. The binary logistic regression analysis shows that age (above 46 years) (p=0.001; AOR (6.60); CI (2.08-20.9) was directly related to the development of DM.


Consistent with other studies, the exclusive non-fasting HbA1c, which is a marker of glycaemic control, only underestimate glycemia in HIV patients with diabetes in this present study. Notwithstanding, HIV patients who are over 40 years are likely to develop DM. As such, screening older individuals diagnosed with HIV is crucial in offering a timely point of care and interventions.

Keywords: Diabetes mellitus, Newly diagnosed HIV-positive patients, HbA1c, South Africa, Glycated haemoglobin, SEMDSA.


Diabetes Mellitus (DM) is a global major public health challenge. Diabetes mellitus, which was a rare disease in rural African settings, has now become a disturbing health issue in subSaharan Africa. In 2017, the International Diabetes Federation (IDF) estimates that the global number of adults with DM will increase by 48% in 2045, and with Africa region projected to have the highest increase of 156% [1]. Similarly, in 2015, an estimated analysis of DM prevalence in Africa shows an increase from 3.2% to 3.7% by 2040 [2]. In South Africa, IDF estimated that 2.3 million people were living with DM in 2015, while a large proportion of people had un diagnosed DM [2]. Perhaps, the surging increases in DM in developing regions of the world could be linked to the ageing population and urbanisation [3]. Again, in 2015, global mortality attributed directly to DM was 5.1 million deaths [2]. Worryingly, over 80% DM associated mortality is prevalent in less developed countries [4] where HIV is hyperendemic [5].

Diabetes mellitus prevalence amongst HIV infected individuals can range from 3.8% [6] to about 15.1% [7]. The literature has indicated that older age, a higher BMI, pre-existing condition such as hypertension [7], the role of antiretroviral therapy (ART) [8, 9], and gender, duration of HIV infection, CD4 count, viral burden, socioeconomic status, culture and body composition indicators [10] are the determinants of increased risk of acquisition of DM in HIV infected individuals. The longer the period of HIV infection, higher viral load of above 5 log copies and a low CD4 count are a direct contributor to the development of DM in HIV positive patients [11]. In addition, co-infection of hepatitis C virus with HIV predisposes one to the development of DM; which is attributed to the production of intrahepatic tumor-necrosis factor with subsequent hepatic steatosis that leads to the development of insulin resistance [12].

Patients could actually present in different ways with HIV and DM; patients diagnosed with DM at the onset of HIV infection, and with hyperglycaemia upon initiating therapy [13]. HIV infected individuals suffer from insulin resistance and not insulin deficiency. It is observed that impaired glucose tolerance and insulin resistance precede the development of weight loss in such patient [14].

HIV-infected individuals who develop the metabolic syndrome (inclusive of DM) exhibit inflammatory and adipocytes problems (elaboration of high levels of C-reactive protein (CRP) and leptin) and lower adiponectin levels which likely result to the pathogenesis of diabetes [9]. Thus, some guidelines advice for the use of fasting and postprandial glucose values for screening and during monitoring of therapy are encouraged [13]. The Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) guideline has advocated for the use of HbA1c for screening for DM because it offers them to make immediate management decisions based on glycaemic control that the patient has achieved over the preceding three months [14], and provides an accurate measure in a non-fasting state. The SEMDSA recommends diagnostic criteria of HbA1c≥6.5% for diabetes [15]. The use of glycated haemoglobin (HbA1c) increases diagnostic accuracy, but the extent of association between HIV and DM might not be clearly delineated [16]. The twin burden of DM and HIV would place a significant economic strain on regions with already poor constrained resources, particularly, in the Eastern Cape Province, which is one of the poorest provinces in South Africa. In addition, the economic implications for patients and their families are enormous. Therefore, diagnosis of DM in newly diagnosed HIV patients is important to inform health managers for optimal management strategies to reduce twin prevalence of diabetes and HIV related morbidity and mortality. In this context, this study aims to determine the proportion of newly diagnosed HIV patients with diabetes mellitus using the HbA1c screening tool in low resource settings in the Eastern Cape, South Africa.


Data from this study was from the ‘Genetic Characteristics of HIV-1, and Determinants of Late Presentation for Care and Prevalence of Diabetes Mellitus among Newly Diagnosed HIV Patients Cohort Study’ in the Eastern Cape, South Africa. The details regarding the setting, design, sample and sampling procedure of this present study have been previously published [17]. Briefly, the study involved 335 randomly selected new HIV-diagnosed patients attending health facilities in the study setting between August 2016 and July 2017. Participants’ demographic information includes age, gender, place of residence, employment status and level of education. In addition, behavioural variables: smoking and alcohol use (past 30 days) was obtained by self-reporting. Information pertaining to HbA1c and other clinical variables was obtained from the medical records of the patients.

The International Society for the Advancement of Kinanthropometry protocol [18] was used to measure the weight and height of the participants. Body weight was measured in light clothing without shoes using a calibrated digital electronic weighing scale (Seca 813, Seca, UK) to the nearest 0.1 kilogram. A calibrated vertical stadiometer (Seca Portable 217 Seca, UK) was used to measure height to the nearest 0.1 centimetre. Body mass index (BMI) was calculated by dividing body weight (kg) by height squared (m2). Overweight and obesity were defined as >25.0kg/m-29.9kg/m2 and ≥30kg/m2, respectively [19]. Diabetes mellitus was defined as HbA1c of ≥6.5% according to the 2017 SEMDSA guideline [15].

2.1. Ethics Approval

The University of Fort Hare Ethical Committee gave ethical approval for the study (REC 270710028RA level 01). Permission was obtained from the Eastern Cape Health Department (Ref: EC_2016RP22_139) prior to data collection. The aim and nature of the study were explained to the participants; and only participants who signed the informed consent form were selected to participate in the study.

2.2. Data Analysis

Descriptive statistics of frequency counts and percentages were applied to summarize the variables. Multiple logistics regression was performed to calculate odds ratios (OR) and 95% confidence interval (CI) to determine the association of demographic variables and HbA1c. A p-value of 0.05 was considered statistically significant. All the statistical analyses were done using the Statistical Package for Social Sciences (SPSS) version 22.0, Chicago, IL, USA.


Of the 335 participants, surveyed analysis was conducted on 330 participants who had completed glycated HbA1c result. The majority of the participants were women (226/69%), single (271/81.4%), unemployed (199/59.6%), and had secondary education (180/54.1%). Of the participants surveyed, 9.6% (32) were under-weight, 155 (46.9%) had normal weight, 60 (18.1%) and 40 (12.1%) were overweight and obese, respectively. Twenty-six percent of the participants consumed alcohol, and less than 20% (57) were smokers (data not shown). The prevalence of newly diagnosed HIV patients with an HbA1c ≥6.5% was 6% Fig. (1). Over half the patients were asymptomatic of any underlying HIV related illness, and about 45% of the patient had a stage 3 or 4 AIDS-defining illness.

Of all the factors in the multivariate analysis, only age (p=0.031) and race (0.019) show a significant association of increased risk of development of DM in newly diagnosed HIV positive patients (Table 1). However, the binary logistic regression analysis (Table 2), shows that age (above 46 years) (p=0.001; AOR (6.60); CI (2.08-20.9) was directly related to the development of DM.

Table 1. Determinants of dm (glycated haemoglobin greater than 6.5%) in newly diagnosed HIV positive patients
Variables HbA1c <6.5 HbA1c ≥6.5 P-value
Age - - -
          <46 years 265 (95.0) 14 (5.0) 0.031
          ≥46 years 45 (86.5) 7 (13.5) -
Sex - - -
          Male 95 (91.3) 9 (8.7) 0.179
          Female 214 (94.7) 12 (5.3) -
Level of Education - - -
          No formal education 39 (92.9) 3 (7.1) 0.738
          Primary 50 (96.2) 2 (3.8) -
          Secondary 168 (94.4) 10 (5.6)
          Tertiary 53 (91.4) 5 (8.6) -
Alcohol use - - -
          Yes 82 (92.1) 7 (7.9) 0.278
          No 227 (94.6) 13 (5.4) -
Smoking - - -
          Yes 52 (91.2) 5 (8.8) 0.361
          No 257 (94.5) 15 (5.5) -
Race - - -
          Black 299 (94.0) 19 (6.0) 0.019
          White 4 (66.7) 2 (33.3) -
          Coloured 7 (100.0) 0 (0.0) -
Employment status - - -
          Unemployed 185 (93.9) 12 (6.1) 0.495
          Employed 125 (93.3) 9 (6.7) -
Body mass index (kg/m2) - - -
          Underweight 28 (87.5) 4 (12.5) 0.528
          Normal weight 145 (93.5) 10 (6.5) -
          Overweight 57 (95.0) 3 (5.0) -
          Obesity 38 (95.0) 2 (5.0) -
WHO clinical stage - - -
          Stage 1 160 (94.7) 9 (5.3) 0.724
          Stage 2 8 (88.9) 1 (11.1) -
          Stage 3 113 (93.4) 8 (6.6) -
          Stage 4 27 (90.0) 3 (10.0) -
Stage at presentation - - -
          Late presentation with advanced disease 108 (92.3) 9 (7.7) 0.728
          Late presenter 77 (95.1) 4 (4.9) -
          Early presenter 123 (93.9) 8 (6.1) -
CD4 Count - - -
          501 and above 63 (92.6) 5 (7.4) 0.531
          350-500 56 (98.2) 1 (1.8) -
          100-349 113 (93.4) 8 (6.6) -
          1-99 56 (93.3) 4 (6.7) -
Table 2. Binary logistic regression showing determinants of abnormal glycated haemoglobin in newly diagnosed hiv positive patients
Variables Beta Wald AOR CI p-value
Age - - - - -
          ≥46 years 1.89 10.24 6.60 2.08-20.94 0.001
          <46 years (Ref) - - - - -
Sex - - - - -
          Male 0.55 0.78 1.73 0.51-5.87 0.377
          Female (Ref) - - - - -
Level of education - - - - -
No formal education -0.82 0.89 0.44 0.08-2.53 0.359
Primary -1.56 0.94 0.21 0.03-1.34 0.098
Secondary -0.96 0.67 0.38 0.10-1.42 0.152
Tertiary (Ref) - - - - -
Alcohol use - - - - -
Yes 0.18 0.07 1.20 0.32-4.47 0.791
No (Ref) - - - - -
Smoking - - - - -
Yes 0.22 0.08 1.25 0.27-5.67 0.775
No (Ref) - - - - -
Employment status - - - - -
          Unemployed -0.39 0.49 0.68 0.23-2.02 0.48
          Employed (Ref) - - - - -
CD4 Count - - - - -
          501 and above 0.461 0.30 1.59 0.30-8.29 0.585
          350-500 -1.16 0.97 0.31 0.03-3.15 0.325
          100-349 0.41 0.35 1.50 0.39-5.80 0.556
          1-99 (Ref) - - - - -
Fig. (1). Diabetes prevalence.


The present study has highlighted a DM prevalence of 6% among newly diagnosed HIV infected individuals. This is lower than Abebe et al. [20] study that compared DM prevalence between pre-ART and patient on ART and reported a higher DM prevalence in the pre-ART population. Similar findings of higher prevalence of DM have been reported in a retrospective database analysis of HIV infected individual in the USA; however, the authors failed to compare between pre-ART patient and ART using patients [6]. HbA1c reflects long-term glucose status of a person with DM. Shortcomings exist regarding its ability to estimate glycemia in an HIV infected individual [21]. Another recommendation was to avoid its use because of high HbA1c-glucose disparity in patients with high mean corpuscular volume (MCV), concurrent NRTI use (esp. abacavir) and low CD4 count [22], explain in the light of the possibility of HIV infected individuals with fast red blood cells turnover. Given the probable incongruence between HbA1c and glycaemic control, fasting blood sugar is clinically desirable DM [21]. One study found HbA1c insensitive, yet a specific diagnostic tool for diabetes in HIV-infected individuals [22]. However, we adopted the use of the HbA1c in this study based on the decreased likelihood of patient presenting to the clinic at a fasting state, and the cross-sectional nature of the study. Other reasons attributed to the poor performance of HbA1c in underestimating glycemia in HIV infected individuals include a high level of haemolysis among HIV infected individuals [20].

In this present study, the majority of the participants above 46 years of age had an increased risk of developing type 2 DM. This was similar to findings in a diverse cohort conducted in the United Kingdom where the risk of developing diabetes was significant in individuals with age above 49 years [7]. The role of ART in the development of type 2 DM has been demonstrated [23], however, our study focused mainly on patients not exposed to ART. In contrast to other studies, the present study found no association between gender, level of education, body mass index, smoking, alcohol use, stage of HIV illness and risk of developing DM [24-26].


The use of HbA1c for the diagnosis of DM in HIV infected individuals might have underestimated glycaemia among the sample in this present study. In addition, the cross-sectional nature of the study limits the ability to draw an association between variables. Additionally, given the small sample size of the study, coupled with the fact that the study was conducted in only five selected health facilities in the Buffalo City Municipality, the findings cannot be generalised to the entire Province nor South Africa.


Notwithstanding, the role of HbA1c in diagnosing diabetes HIV infected individuals. The present study demonstrates a low prevalence of DM among newly diagnosed HIV patients in this understudied, and resource-limited setting. In addition, increasing age is a likely factor for the development of DM among the participants. Therefore, regular screening of newly diagnosed HIV positive patients for DM is important for timely health care interventions.


The University of Fort Hare Ethical Committee gave ethical approval for the study (REC 270710028RA level 01). Permission was obtained from the Eastern Cape Health Department (Ref: EC_2016RP22_139) prior to data collection.


No animals were used in this research. All human research procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national), and with the Helsinki Declaration of 1975, as revised in 2013.


Wrtten informed consent was obtained from all participants.


The authors confirm that the data supporting the findings of this research are available within the article.


Financial support was received from the Discovery Foundation and South Africa Medical Research Council (#SAMRC/UFH/P790) for this study.


The authors declare that there is no conflict of interest, financial or otherwise.


We would like to thank the staff of the Eastern Cape Department of Health for their help rendered during data collection. Finally, the participants for agreeing to participate in this study.


[1] IDF Diabetes Atlas, 8 ed Int Diabetes Fed 2017 [12 March 2019];
[2] IDF Diabetes Atlas, 7 ed Int Diabetes Fed 2015 [12 March 2019];
[3] Mbanya JCN, Motala AA, Sobngwi E, Assah FK, Enoru ST. Diabetes in sub-Saharan Africa. Lancet 2010; 375(9733): 2254-66.
[4] Global Health Observatory Data Repository 2014 [10 April 2017];
[5] Global AIDS Report2012 http:// sites / default / files/media_asset /20121120_UNAIDS_Global_Report_2012_with_annexes_en_1.pdf2017 [23 May 2017];
[6] Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM, Skarbinski J. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010. BMJ Open Diabetes Res Care 2017; 5(1)e000304
[7] Duncan AD, Goff LM, Peters BS. Type 2 diabetes prevalence and its risk factors in HIV: A cross-sectional study. PLoS One 2018; 13(3)e0194199
[8] Salehian B, Bilas J, Bazargan M, Abbasian M. Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors. J Natl Med Assoc 2005; 97(8): 1088-92.
[9] Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50(5): 499-505.
[10] Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45(1): 111-9.
[11] Butt AA, McGinnis K, Rodriguez-Barradas MC, et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23(10): 1227-34.
[12] Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18(14): 1642-51.
[13] Kalra S, Unnikrishnan AG, Raza SA, et al. South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian J Endocrinol Metab 2011; 15(4): 242-50.
[14] Pillay S, Aldous CM, Singh D, Pillay D. Validation and effect on diabetes control of glycated haemoglobin (HbA1c) point of care testing. South Afr Med J 2019; 109(2): 112-5.
[15] Type SEMDSA. 2 Diabetes Guilines Expert Committee. Chapter 3: Screening and diagnosis of type 2 diabetes and intermediate hyperglycaemia. J Endocrin Metabol Diabetes South Africa 2017; 22(1): S1-S19.
[16] Spollett GR. Hyperglycemia in HIV/AIDS. Diabetes Spectr 2006; 19(3): 163-6.
[17] Tien PC, Schneider MF, Cox C, et al. Association of HIV infection with incident diabetes mellitus: impact of using hemoglobin A1C as a criterion for diabetes. J Acquir Immune Defic Syndr 2012; 61(3): 334-40.
[18] Sogbanmu OO, Goon DT, Obi LC, et al. Socio-demographic and clinical determinants of late presentation among patients newly diagnosed with HIV in the Eastern Cape South Africa Medicine 2019; 98(8)e14664
[19] Stewart A, Marfell-Jones M, Olds T, de Ridder H. International standards for anthropometric assessment 2011.
[20] 2012Defining Adult Overweight and Obesity [9 July 2017]; http/ / / obesity/ adult/ defining.html
[21] Abebe SM, Getachew A, Fasika S, Bayisa M, Girma Demisse A, Mesfin N. Diabetes mellitus among HIV-infected individuals in follow-up care at University of Gondar Hospital, Northwest Ethiopia. BMJ Open 2016; 6(8)e011175
[22] Kim SY, Friedmann P, Seth A, et al. Monitoring HIV-infected patients with diabetes: haemoglobin A1c, fructosamine, or glucose? Clin Med Insights: Endocrinol Diabet 2014; 7(CMED-S19202)
[23] Avari P, Devendra S. Human immunodeficiency virus and type 2 diabetes. London J Prim Care (Abingdon) 2017; 9(3): 38-42.
[24] Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS Patient Care STDS 2012; 26(4): 197-201.
[25] Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444(7121): 881-7.
[26] Grinspoon S. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 2003; 37(Suppl_2): S85-90.